BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday

BridgeBio Pharma (NASDAQ:BBIO) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect BridgeBio Pharma to post earnings of ($0.73) per share and revenue of $150.7110 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 20, 2026 at 12:30 PM ET.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $73.33 on Thursday. The firm has a market cap of $14.13 billion, a price-to-earnings ratio of -17.54 and a beta of 1.13. BridgeBio Pharma has a 1 year low of $28.33 and a 1 year high of $81.32. The firm’s 50 day moving average price is $75.54 and its two-hundred day moving average price is $62.79.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BBIO. Piper Sandler upped their target price on BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Wells Fargo & Company raised their target price on shares of BridgeBio Pharma from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Evercore restated an “outperform” rating on shares of BridgeBio Pharma in a report on Monday, October 27th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of BridgeBio Pharma in a research note on Monday, November 3rd. Finally, Sanford C. Bernstein started coverage on shares of BridgeBio Pharma in a research report on Thursday, December 11th. They set an “outperform” rating and a $94.00 price objective on the stock. Twenty-two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.05.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Thomas Trimarchi sold 16,934 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $66.46, for a total value of $1,125,433.64. Following the completion of the transaction, the chief financial officer directly owned 382,830 shares of the company’s stock, valued at approximately $25,442,881.80. The trade was a 4.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $66.65, for a total value of $666,500.00. Following the completion of the sale, the director owned 11,589 shares of the company’s stock, valued at approximately $772,406.85. The trade was a 46.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 260,700 shares of company stock worth $18,157,071. 18.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BBIO. Meeder Advisory Services Inc. acquired a new position in BridgeBio Pharma during the fourth quarter valued at approximately $290,000. Inceptionr LLC grew its stake in shares of BridgeBio Pharma by 13.7% in the fourth quarter. Inceptionr LLC now owns 5,995 shares of the company’s stock valued at $459,000 after buying an additional 723 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in BridgeBio Pharma during the fourth quarter worth $1,959,000. LPL Financial LLC lifted its stake in BridgeBio Pharma by 16.1% in the fourth quarter. LPL Financial LLC now owns 13,350 shares of the company’s stock valued at $1,021,000 after acquiring an additional 1,847 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in shares of BridgeBio Pharma by 16.0% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 14,677 shares of the company’s stock valued at $1,123,000 after acquiring an additional 2,025 shares during the period. 99.85% of the stock is currently owned by institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.